Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy Subjects
Michael A Eldon, Edwin L Parsley, Mari Maurer, Thomas E Tarara, Jerry Okikawa, Jeffry G Weers, Michael A Eldon, Edwin L Parsley, Mari Maurer, Thomas E Tarara, Jerry Okikawa, Jeffry G Weers
Abstract
Background: RT234 (vardenafil inhalation powder) is being developed for pulmonary administration "as needed", to acutely improve exercise tolerance and symptoms in patients with pulmonary arterial hypertension (PAH). Methods: This single-center, open-label, randomized study in 32 healthy adult subjects evaluated single and multiple inhalation doses of RT234, for safety, tolerability, and pharmacokinetics (PKs). Results: RT234 was generally safe and well tolerated at single doses of 0.2-2.4 mg and after repeated dose administration of up to 2.4 mg q4h for four doses daily for 9 days. The most common treatment-emergent adverse events were mild-to-moderate headaches. There was no evidence of pulmonary irritation or inflammation. Vardenafil was absorbed very rapidly after inhalation as RT234, independent of dose level and number of doses administered. The tmax occurred at the time that the first blood sample following completion of dosing. After Cmax was achieved, plasma vardenafil concentrations declined rapidly in an exponential fashion that appeared to be parallel among dose levels. Vardenafil plasma concentrations and PK parameters increased in a dose-proportional manner. Vardenafil systemic exposure was notably greater after oral administration of 20 mg vardenafil tablets (Levitra®) than after administration of any dose level of RT234. During repeated dose administration of RT234, Cmax was attained rapidly following each dose and in a pattern similar to that observed after single-dose administration. Minor accumulation, characterized by very low mean morning predose vardenafil concentrations (<0.5 ng/mL), occurred after q4h dosing of up to four doses per day for 9 days. Taken together, these findings show that no clinically important vardenafil accumulation is likely after repeated-dose administration of RT234. Mean vardenafil t1/2 values were comparable after single- and repeated-dose administration. Conclusions: Comparative plasma vardenafil bioavailability data from this study provide scientific justification for reliance on Food and Drug Administration findings for Levitra tablets. These findings support further evaluation of RT234 for as-needed treatment of patients with PAH. The Clinical Trials Registration number is ACTRN12618001077257.
Keywords: inhalation; pharmacokinetics; pulmonary arterial hypertension; vardenafil.
Conflict of interest statement
The authors declare they have no competing financial interests.
Figures
References
- Farber HW, and Loscalzo J: Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655–1665
- Galie N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, and Hoeper M: 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015;44:903–975
- Frumkin LR: The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev. 2012;64:583–620
- Feldman J: Pulmonary arterial hypertension life expectancy & survival rates. 2018. , accessed November27, 2020
- The Voice of the Patient. A series of reports from the U.S. Food and Drug Administration's (FDA's) Patient Focused Development initiative: Pulmonary Arterial Hypertension. May 13, 2014. , accessed November27, 2020
- Kuhn E, and Lavielle M: Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal. 2005;49:1020–1038
- Gibaldi M, and Perrier D: Pharmacokinetics, 2nd edition. Informa Healthcare USA, New York, 2007
- Patton JS, Fishburn CS, and Weers JG: The lungs as a portal of entry for systemic drug delivery. Proc Am Thor Soc. 2004;1:338–344
- Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, and Forgue ST: Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;10:1278–1283
- Center for Drug Evaluation and Research Approval package for: Application Number 21-400. Clinical Pharmacology and Biopharmaceutics Review. , accessed November27, 2020
- Levitra – vardenafil hydrochloride tablet, film-coated, GlaxoSmithkline LLC. , accessed November27, 2020
- Jing Z-C, Yu Z-X, Shen J-Y, Wu B-X, Xu K-F, Zhu X-Y, Pan L, Zhang Z-L, Liu X-Q, Zhang Y-S, Jiang X, and Nazzareno Galie'10 for the Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group: Vardenafil in pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011;183:1723–1729
- Henrohn DM, Sandqvist A, Hedeland M, Egeröd H, Bondesson U, and Wikström G: Acute haemodynamic response in relation to plasma vardenafil concentrations in patients with pulmonary hypertension. Br J Clin Pharmacol. 2012;74:990–998
- Keogh A, Dwyer N, Kotlyar E, Maurer M, Weers J, and Parsley E: Acute hemodynamic improvement in chronic pulmonary arterial hypertension on dual therapy following RT234 inhalation. Chest. 2020;158:A2162–A2163(abstract).
- Ghofrani PD, Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadaş B, Schermuly RT, Weissmann N, Seeger W, and Grimminger F: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2004;44:1488–1496
- Corbin JD, Beasley A, Blount MA, and Francis SH: Vardenafil: Structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem Int. 2004;45:859–863
- Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, and Corbin JD: Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol. 2004;66:144–152
- Sandner P, Wollenschlager A, and Neuser D: PDE inhibitors for the treatment of pulmonary hypertension. World Patent Application. 2009;WO2009/115235
- deTejada IS: Vardenafil duration of action. Eur Urol. 2006;50:901–902
- Porst H, Sharlip ID, Hatzichristou D, Rubio-Aurioles E, Gittelman M, Stancil B-N, Smith PM, Wilkins HJ, and Pommerville P: Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: A randomized, double-blind, placebo-controlled study. Eur Urol. 2006;50:1086–1095
- Mehrotra N, Gupta M, Kovar A, and Meibohm B: The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res. 2007;19:253–264
Source: PubMed